In A549 cells, Quisinostat treatment yielded cell viability IC50 values of 82.4 and 42.0 nM after 48 and 72 h, respectively, and reduced migrating-cell measurements relative to control cells. In HCC1569 cells, Quisinostat induced detectable gene expression changes by 30 min, followed by a progressive increase in differentially expressed genes over time. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell viability in lung cancer cells
Cell-based study · A549 cells [1]
A549 cells were treated with Quisinostat and assessed for cell viability. After 48 and 72 h of treatment, IC50 values were 82.4 and 42.0 nM, respectively.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5, 10, 20, 40, 60, 80, 100, 125, 250, and 500 nM
- Exposure duration
- 24, 48, or 72 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Quisinostat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Quisinostat inhibited the viability of A549 cells (S50, S51, S52, S53)
cell viability: cell viability; comparator: control cells — Results > Quisinostat inhibited the viability of A549 cells (S50, S53)
Gene expression changes in HCC1569 cells
Cell-based study · HCC1569 cells [2]
HCC1569 cells were treated with 100 nM Quisinostat and assessed by RNA-seq analysis. Detectable gene expression changes appeared by 30 min, with the number of differentially expressed genes increasing progressively over time.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 nM
- Exposure duration
- 30 min, 1 h, 3 h and 10 h of treatment
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Quisinostat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Self-renewal-associated oncogenic pathways regulated by H1.0 (S71, S72, S73); Methods > RNA sequencing and quantitative RT-PCR (S267, S276, S277)
RNA-seq analysis: RNA-seq analysis; comparator: DMSO-treated control cells — Results > Self-renewal-associated oncogenic pathways regulated by H1.0 (S71, S73); Methods > RNA sequencing and quantitative RT-PCR (S267, S277)
Migration in lung cancer cells
Cell-based study · A549 cells [1]
A549 cells were treated with Quisinostat for 24 h. Migrating cells decreased relative to control group cells across the tested concentrations.
Literature-Reported Treatment Conditions
- Treatment concentration
- 25, 50, and 100 nM
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Quisinostat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Quisinostat inhibited A549 cell migration by suppressing EMT process (S72, S73)
OD values of crystal violet: OD values of crystal violet; comparator: control group cells — Results > Quisinostat inhibited A549 cell migration by suppressing EMT process (S73)